Overview
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
Status:
Recruiting
Recruiting
Trial end date:
2023-05-01
2023-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Arena Pharmaceuticals
Criteria
Inclusion Criteria:- Diagnosed with Ulcerative Colitis (UC) ≥ 3 months prior to screening
- Active UC confirmed by endoscopy
- Moderately active UC defined as a modified Mayo score of 4 to 6 and an endoscopic
score ≥ 1
- Received a surveillance colonoscopy within 12 months before baseline
Exclusion Criteria:
- Severe extensive colitis
- Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a
fistula consistent with Crohn's disease
- Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
- Hospitalization for exacerbation of UC requiring intravenous steroids within 12 weeks
prior to or after screening